コーパス検索結果 (left1)
通し番号をクリックするとPubMedの該当ページを表示します
1 In this first-in-human study, up to 10 cycles of AMG 420 were given (4-week infusions/6-week cycles).
3 onkeys received a primary intranasal infection with RSV and were given a boost with RSV or a parainfluenza virus (PIV) ve
4 Of 807 participants who underwent RYGB and were given an activity monitor, 649 (80%) had sufficient data
7 ted activity coefficients derived from time-activity curves were given as input to OLINDA/EXM for dose calculations.
8 with myeloid-specific disruption of Lacc1 (Lacc1(Deltamye)) were given oral Salmonella Typhimurium or dextran sodium sulf
11 hospital admission also increased significantly when drugs were given intravenously but not intraosseously, and favored
14 ritonavir-boosted darunavir (n=384), and 383 in both groups were given at least one dose of their allocated treatment.
15 Leukemia inhibitory factor (LIF) injections were given intraperitoneally and implantation sites visualize
17 Ib, pembrolizumab (200 mg) and bevacizumab (10 or 15 mg/kg) were given intravenously every 3 weeks.
23 taneously injected into Cdh11(+/+) (C57BL/6J) mice and mice were given injections of antibody against CDH11, gemcitabine,
24 otopic tumors were grown from K8484 cells in mice, and mice were given injections of neutralizing antibodies against chem
25 implanted into interscapular fat pads of NSG mice, and mice were given injections of penfluridol daily for 28 days.
30 and intestinal recycling perfusion was measured; some mice were given dextran sodium sulfate to induce colitis and/or ga
32 cells were injected into livers of C57BL/6 mice; some mice were given intraperitoneal injections of antibodies against P
33 were given intravenously; brentuximab vedotin and nivolumab were given every 3 weeks, ipilimumab was given every 6 weeks
35 rbonyl-1,4-dihydrocollidine to induce cholestatic injury or were given carbon tetrachloride to induce liver fibrosis.
39 n period, family members enrolled in the intervention phase were given an informational booklet outlining opportunities f
41 Outcomes were compared from the time exception points were given, which we defined as conditional waitlist outcomes
44 y but later progression on aromatase inhibitor (AI) therapy were given vorinostat (400 mg daily) sequentially or simultan
45 aemophilus influenza type b-hepatitis B combination vaccine were given at 2, 3, and 4 months after birth followed by a bo
46 old change of 0.64 [95% CI 0.39 to 0.89]; p=0.0002) and who were given placebo (0.62 [0.34 to 0.91]; p=0.0001).
48 We included mechanically ventilated ICU patients who were given moderate-to-high doses of opioids and expected to
50 determined to be refugees or parolees in Cuba and those who were given parole status after arrival.